Celltrion will use Oracle Health platforms to help streamline regulatory reporting processes regarding drug safety and efficacy, Oracle said Tuesday.
"It is great to see the biopharmaceutical market headed in new and innovative directions as with the emergence of more biosimilar manufacturers," said Steve Rosenberg, general manager of Oracle Health Sciences. "Celltrion is a glowing example of a biotech company that is innovating to help improve people's lives."
Celltrion셀트리온 will use two platforms from the platform service provider – Oracle Health Sciences Argus and Oracle Health Sciences Empirica Signal – to help monitor the effects of its licensed drugs to identify and evaluate previously unreported adverse reactions.
An essential aspect of getting biosimilar drugs to the market is safety and efficacy reporting to regulatory bodies. Celltrion will now rely on Oracle Health Sciences to bring these therapies to global markets more cost-effectively, it said.
"Since our founding in 2002, we have remained committed to making more advanced therapeutics available to everyone, and have turned to technology to help us achieve our goals,” said Lee Sang-joon, vice president of Celltrion.
He went on to say, “Oracle Health Sciences technology is supporting us in meeting today's regulatory requirements and will enable us to move and shift as the regulatory landscape evolves so that we can bring more life-saving and treatments to market safely and cost-effectively."
<© Korea Biomedical Review, All rights reserved.>